Magellan Health has announced the launch of reSET therapy, a pilot initiative using the first-ever FDA cleared prescription digital therapeutic from PEAR Therapeutics to improve outcomes for individuals struggling with Substance Use Disorders (SUD) and other related conditions.
With the current challenges in our nation related to substance use, the evidence-based, non-drug treatment option presented with this approach is an opportunity to offer a practical solution to meet these complex needs and rethink the way treatment is delivered today.
The pilot program will enroll 250 patients with SUD and offer each patient a 12-week course of reSET therapy. The collaboration aims to examine patient abstinence and program retention through increased engagement and therapy adherence. The pilot will use advanced data analytics generated through the reSET therapy and accompanying clinician dashboards to more effectively provide technical support and clinical outreach to both treatment providers and their patients. Magellan will also work with PEAR to develop a series of publications highlighting the operational, economic and clinical results of this pilot program.
Magellan believes this pilot will help support the broader strategy to engage consumers in ways that match the best of new and traditional methods to drive optimal outcomes. This pilot will be important to help understand the value such FDA approved solutions bring to the healthcare market, as well as the operational requirements needed to support digital therapeutics in the future.
According to the Substance Abuse and Mental Health Services Administration (SAMHSA), approximately 20.2 million adults have a type of SUD in the United States. Cognitive behavioral therapy, such as reSET®, is widely recognized as an important component of an overall treatment regimen for SUD. reSET® is a 12-week duration, FDA-cleared prescription digital therapeutic to be used in conjunction with standard outpatient treatment for substance use disorder related to stimulants, cannabis, cocaine, and alcohol.
This product combines patient-facing interventions and assessments via a mobile device, with clinician-facing dashboards and data analytics on the back-end. reSET® has been shown in clinical studies to increase abstinence from a patient’s substances of abuse during treatment and increase patient retention in the outpatient treatment program. reSET® provides access to self-reported substance use, triggers, cravings and outcomes to the patient’s medical provider.
“This is an important collaboration for PEAR as we seek to bring reSET to patients with SUD,” said Corey McCann, M.D., Ph.D., president and chief executive officer of PEAR Therapeutics. “We believe that prescription digital therapeutics hold great promise in improving patient outcomes across a wide range of central nervous system disorders including psychiatry, neurology and pain, and will become a vital part of tomorrow’s treatment paradigm across all disease areas. Collaborating with a company like Magellan will help PEAR get this innovative solution to patients who need it most.”